OVERCOMING THE CHALLENGES IN THE CURRENT TREATMENT OF RETINAL DISEASES
Our Solution
Everads platform access method and delivery system provide excellent drug distribution and potential long-term therapeutic effects and improves patient compliance and outcomes.
Everads delivery system overcomes significant technical challenges in effective suprachoroidal injection and provides superior outcomes as compared to today’s intravitreal and subretinal injections.
About Evards
Everads Therapy is an early-stage life sciences company developing the next generation of retinal treatment delivery technologies. With the goal of overcoming significant challenges in current treatment methodologies for retinal and macular diseases, Everads' delivery system...
Evards News
(March 12, 2020)
Everads Therapy Enters Into Option Agreement With Global Pharma Company to License Everads' Suprachoroidal Delivery System for Retinal Disease Therapies;
- Agreement Supports Potential of Everads' Novel Technology and Method for Delivery of Posterior Segment Therapeutics to the Suprachoroidal Space.
(March 22, 2022)
Ophthalmology Times: "Suprachoroidal delivery system gets drug to the macula, posterior segment"
(June 30, 2021)
Everads Enters into Collaboration to Evaluate its Suprachoroidal Delivery Technology with a Clinical-Stage Gene Therapy Company
- Under new collaboration, partner given opt-in right to license specific retinal targets in exchange for pre-agreed license fees, development milestones and royalties
- Agreement follows a previously-announced option deal with a global pharmaceutical company evaluating Everads' technology
